2024-09-22 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of products, including pharmaceuticals, medical devices, nutritionals, and diagnostics.

**Performance Analysis:**

1. **Performance vs. S&P 500 (VOO):** 
    * ABT has underperformed the S&P 500 (VOO) by **-28.41%** over the period considered.
    * The current relative divergence of **13.96%** indicates that ABT's performance is relatively closer to the S&P 500's performance compared to the historical range.

2. **Recent Price Movements:** 
    * ABT closed at **$113.7**, below its **5-day** ($115.46) and **20-day** ($114.71) moving averages, but above its **60-day** ($109.12) moving average. This suggests a recent decline in price but potential for recovery.

3. **Technical Indicators:** 
    * **RSI:** 51.57, suggesting ABT is neither overbought nor oversold, currently in a neutral zone.
    * **PPO:** -0.41, indicating potential for further decline, but relatively close to the zero line, suggesting a potential for a rebound.
    * **Delta_Previous_Relative_Divergence:** -2.04, indicating a recent short-term downtrend.
    * **Expected Return:** 70.72%, indicating a potential 5-year maximum return based on current investment.

4. **Recent Earnings and Outlook:**
    * **Latest Earnings:** 
        * **Date:** 2024-07-31
        * **EPS:** $0.74 (**missed estimates by $0.01**)
        * **Revenue:** $10.38B (**met estimates**)
    * **Overall:** Abbott Laboratories' most recent earnings release showed mixed results, with EPS slightly missing expectations but revenue meeting expectations. The company's overall performance seems to be stable, with a history of consistent revenue growth. 

**Overall Analysis:**

ABT has shown recent underperformance compared to the S&P 500 (VOO) and has experienced a recent decline in price. However, technical indicators suggest a potential for recovery, with the RSI and PPO indicating a neutral zone and close to a potential rebound. The latest earnings results show mixed performance, but the company has a history of consistent revenue growth. The overall outlook for ABT remains positive, supported by a strong market position in the healthcare sector and the potential for further growth. 

**Disclaimer:** This report provides a general overview of ABT and is not intended as investment advice. Investors should conduct their own research and consider their individual financial circumstances before making any investment decisions. 
